Functional memory CD4 T cells in peripheral blood at baseline and increased proportions of Ki-67+ CD4 T cells after anti-PD-1/PD-L1 have been associated with better responses to treatment in NSCLC patients (106). This evidence concerns the gene CD274 and non-small cell lung carcinoma.